University of South Carolina School of Medicine, Columbia, South Carolina.
Department of Medicine, Palmetto Health USC Medical Group, Columbia, South Carolina.
Pharmacotherapy. 2018 Jan;38(1):42-50. doi: 10.1002/phar.2054. Epub 2017 Dec 11.
Retrospective matched-cohort study evaluating association between penicillin allergy and empirical carbapenem use in gram-negative bloodstream infections (BSIs) and utility of antimicrobial stewardship interventions in reducing carbapenem utilization.
Hospitalized adults with community-onset gram-negative BSI from January 1, 2010, to June 30, 2015, at two large community hospitals in Columbia, SC, were identified. Antimicrobial stewardship interventions targeting penicillin allergy and carbapenem utilization were fully implemented January 1, 2014. Multivariate logistic regression was used to examine impact of penicillin allergy and antimicrobial stewardship interventions on empirical carbapenem use. Kaplan-Meier analysis was used to evaluate time to carbapenem deescalation in patients with penicillin allergy before and after interventions.
Patients with penicillin allergy (n=140) were more likely to receive empirical carbapenem therapy for community-onset gram-negative BSI compared to those without penicillin allergy (n=140) (27% vs 12%, p=0.002). After adjustments in the multivariate model, penicillin allergy (odds ratio [OR] 3.98, 95% confidence interval [CI] 1.98-8.45) and prior β-lactam use (OR 2.72, 95% CI 1.07-6.64) were independently associated with empirical carbapenem use, whereas antimicrobial stewardship interventions were associated with decline in carbapenem utilization (OR 0.41, 95% CI 0.16-0.94). Among patients with penicillin allergy who were prescribed empirical carbapenems, median time to carbapenem deescalation was significantly shorter in the postintervention versus preintervention period (2.0 vs 4.2 days, p=0.004).
Penicillin allergy was a significant contributor to carbapenem use in community-onset gram-negative BSI. This was subject to modification by antimicrobial stewardship interventions, which successfully reduced overall carbapenem use and duration of carbapenem therapy in patients with penicillin allergy.
回顾性匹配队列研究评估青霉素过敏与革兰氏阴性菌血流感染(BSI)经验性碳青霉烯类药物使用之间的关联,以及抗菌药物管理干预在减少碳青霉烯类药物使用方面的作用。
2010 年 1 月 1 日至 2015 年 6 月 30 日,在南卡罗来纳州哥伦比亚的两家大型社区医院,确定了社区获得性革兰氏阴性菌 BSI 的住院成人患者。2014 年 1 月 1 日,全面实施了针对青霉素过敏和碳青霉烯类药物使用的抗菌药物管理干预措施。采用多变量逻辑回归分析来检验青霉素过敏和抗菌药物管理干预对经验性碳青霉烯类药物使用的影响。采用 Kaplan-Meier 分析评估干预前后青霉素过敏患者碳青霉烯类药物降级的时间。
与无青霉素过敏的患者(n=140)相比,有青霉素过敏的患者(n=140)更有可能接受经验性碳青霉烯类药物治疗社区获得性革兰氏阴性菌 BSI(27%比 12%,p=0.002)。在多变量模型调整后,青霉素过敏(比值比[OR]3.98,95%置信区间[CI]1.98-8.45)和既往β-内酰胺类药物使用(OR 2.72,95%CI 1.07-6.64)与经验性碳青霉烯类药物使用独立相关,而抗菌药物管理干预与碳青霉烯类药物使用减少相关(OR 0.41,95%CI 0.16-0.94)。在接受经验性碳青霉烯类药物治疗的青霉素过敏患者中,干预后与干预前相比,碳青霉烯类药物降级的中位时间明显缩短(2.0 天比 4.2 天,p=0.004)。
青霉素过敏是社区获得性革兰氏阴性菌 BSI 碳青霉烯类药物使用的重要原因。抗菌药物管理干预可以对此进行修正,成功减少了青霉素过敏患者的总体碳青霉烯类药物使用量和碳青霉烯类药物治疗时间。